Dirlotapide

Usage

It is supplied as an oral solution. It is not intended for use in humans, cats, birds, rodents, or other animals.

Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma.

Regulation and safety

On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.

However, concerns have since been raised, since 2010, about adverse effects that might more strongly affect particular breeds.

Dirlotapide (under the brand name Slentrol) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but has since been withdrawn from the market in the EU.

References

References

1. "Slentrol (dirlotapide) Oral Solution (5 mg/ml, 1%) for Use in Dogs Only. Full Prescribing Information". Pfizer Animal Health. Div. of Pfizer Inc. NY, NY 10017.
2. "Carbocyclic- and Heterocyclic-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds".
3. (May 2007). "Dirlotapide, a U.S. Food and Drug Administration-approved first-in-class obesity drug for dogs-will humans be next?". Journal of Diabetes Science and Technology.
4. Bridges, Andrew. "FDA approves 1st drug for obese dogs".
5. (15 October 2010). "Why Pfizer Doesn't Want the FDA Studying Its Diet Drug for Dogs". CBS News.
6. (14 October 2010). "FDA Sniffing Around Pfizer's Doggy Weight-Loss Drug Slentrol". WSJ.
7. (October 2016). "Weight management in obese pets: the tailoring concept and how it can improve results". Acta Veterinaria Scandinavica.